Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sangeetha M Reddy

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Frontiers in Cell and Developmental Biology|June 3, 2024
Digital droplet PCR analysis of organoids generated from mouse mammary tumors demonstrates proof-of-concept capture of tumor heterogeneityKatherine E Lake, Megan M Colonnetta, Clayton A Smith, et al.
Cell Reports. Medicine|April 13, 2024
A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy responseLily Xu, Kaitlyn Saunders, Shao-Po Huang, et al.
Genome Medicine|April 27, 2021
Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancersXiaotong Li, Sushant Kumar, Arif Harmanci, et al.
Cancer Research|August 19, 2017
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic CellsVictor A Gall, Anne V Philips, Na Qiao, et al.
Cancer Discovery|October 9, 2025
HIF-2-Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell CarcinomaArijit Mal, Bingqing Xie, Zane Gray, et al.
Cancer Immunology Research|May 3, 2019
Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast CancerSangeetha M Reddy, Alexandre Reuben, Souptik Barua, et al.
Communications Medicine|August 5, 2025
A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer StudyHannah L Chang, Meng Cao, Mir Lim, et al.
Nature Communications|May 13, 2025
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitorsThomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Cancer Immunology Research|May 13, 2022
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast CancerKyung-Min Lee, Chang-Ching Lin, Alberto Servetto, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Frontiers in Cell and Developmental Biology|June 3, 2024
Digital droplet PCR analysis of organoids generated from mouse mammary tumors demonstrates proof-of-concept capture of tumor heterogeneityKatherine E Lake, Megan M Colonnetta, Clayton A Smith, et al.
Cell Reports. Medicine|April 13, 2024
A comprehensive single-cell breast tumor atlas defines epithelial and immune heterogeneity and interactions predicting anti-PD-1 therapy responseLily Xu, Kaitlyn Saunders, Shao-Po Huang, et al.
Genome Medicine|April 27, 2021
Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancersXiaotong Li, Sushant Kumar, Arif Harmanci, et al.
Cancer Research|August 19, 2017
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic CellsVictor A Gall, Anne V Philips, Na Qiao, et al.
Cancer Discovery|October 9, 2025
HIF-2-Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell CarcinomaArijit Mal, Bingqing Xie, Zane Gray, et al.
Cancer Immunology Research|May 3, 2019
Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast CancerSangeetha M Reddy, Alexandre Reuben, Souptik Barua, et al.
Communications Medicine|August 5, 2025
A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer StudyHannah L Chang, Meng Cao, Mir Lim, et al.
Nature Communications|May 13, 2025
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)Romualdo Barroso-Sousa, Jorge Gomez Tejeda Zanudo, Tianyu Li, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitorsThomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Cancer Immunology Research|May 13, 2022
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast CancerKyung-Min Lee, Chang-Ching Lin, Alberto Servetto, et al.
Pageof 3